RecruitingPhase 1interventionalRules rewrite

Phase 1: testing ST-01156 for Advanced Solid Tumors

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Official registry: https://clinicaltrials.gov/study/NCT07197554 · SEED Therapeutics, Inc. · enrollment listed as 171

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are ST-01156. The registry lists allocation as na. A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

They plan to enroll about 171 people at 6 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Interventions: ST-01156

Primary outcome (registry wording): Part 1: Dose Escalation

Who it is for (from inclusion criteria)

Ages 16 Years to any
Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old
Has a metastatic or locally advanced and unresectable solid tumor
Has at least 1 measurable lesion or evaluable disease per RECIST v1.1
Has an how well you can do daily activities (ECOG score) ≤ 2 at screening
Has adequate organ function as defined in the protocol

Who the registry excludes

Has received prior radiotherapy within 2 weeks of treatment
Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable
Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter
Had major surgery within 28 days before study therapy administration
Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy
Has previously received a RBM39 inhibitor/degrader

Public study contact (from the registry)

Dr. Eric Rowinsky Chief Medical Officer

(908) 883-0647

erowinsky@oncodrugs.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

6 listed

The City of Hope National Medical Center — Duarte, California (recruiting)
Hoag Memorial Hospital — Newport Beach, California (recruiting)
Mass General Brigham Cancer Institute — Boston, Massachusetts (recruiting)
Dana Farber Cancer Institute — Boston, Massachusetts (recruiting)
Memorial Sloan Kettering Cancer Center — New York, New York (recruiting)
The University of Texas MD Anderson Cancer Center — Houston, Texas (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Collection of Blood From Patients With Cancer

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.

NCT00034216 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup.

NCT00451022 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Natural History of Noncirrhotic Portal Hypertension

Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.

NCT02417740 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

FAQ about this NCT record

Is NCT07197554 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07197554?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07197554?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary